Hydrochlorothiazide/Lisinopril Shortage: What Providers and Prescribers Need to Know in 2026

Hydrochlorothiazide/Lisinopril (generic Zestoretic/Prinzide) is one of the most widely prescribed antihypertensive combination tablets in the United States. While no active FDA or ASHP shortage is declared as of 2026, prescribers are regularly fielding calls from patients who cannot find their specific strength at their usual pharmacy. This guide provides a clinical framework for managing these situations efficiently.

Current Availability Status (2026)

As of early 2026, the national supply of generic Hydrochlorothiazide/Lisinopril is stable. Multiple manufacturers — including major generic producers like Teva, Mylan (Viatris), Aurobindo, and others — supply this combination tablet. It is not on the FDA Drug Shortage Database or the ASHP shortage tracking list. However, prescribers should be aware that:

• Individual pharmacy locations, particularly chain locations on tight distributor contracts, can be temporarily out of specific strengths (most commonly 20mg/12.5mg).
• Independent pharmacies with multi-wholesaler relationships (McKesson, Cardinal Health, AmerisourceBergen) typically have more reliable access.
• Mail-order pharmacies (Express Scripts, OptumRx, Amazon Pharmacy) maintain larger inventory buffers for maintenance medications.

Available Strengths and Formulations

Hydrochlorothiazide/Lisinopril is available as an oral tablet in three fixed-dose strengths:

• 10mg lisinopril / 12.5mg HCTZ — initial-step combination dose
• 20mg lisinopril / 12.5mg HCTZ — most commonly dispensed strength
• 20mg lisinopril / 25mg HCTZ — higher HCTZ dose for more resistant hypertension

Maximum daily dose is 80mg lisinopril / 50mg HCTZ. Dose titration should occur every 2-3 weeks based on clinical response. This combination is not recommended as initial antihypertensive therapy — it is indicated for patients who have not achieved adequate BP control on either component alone.

Clinical Alternatives When the Combination Tablet Is Unavailable

When a patient cannot source their combination tablet, the following approaches are clinically equivalent and widely available:

1. Prescribe the Components Separately

The simplest solution: prescribe lisinopril and hydrochlorothiazide as individual tablets at equivalent doses. Both components are widely available generics, available at essentially every pharmacy in the country, and cost under $10/month each with discount coupons. Bioavailability and clinical effect are identical. The only consideration is potential impact on adherence for patients who prefer single-pill regimens.

2. Switch to Losartan/HCTZ (Hyzaar)

Losartan/HCTZ (generic Hyzaar) is the most commonly substituted combination antihypertensive. Key clinical considerations: losartan is an ARB, not an ACE inhibitor, and avoids bradykinin-mediated cough. For patients with ACE inhibitor cough, this is often a preferred permanent switch rather than a temporary bridge. Losartan is available in 50mg/12.5mg and 100mg/25mg strengths. Equivalent blood pressure reduction is generally achievable; monitor BP and electrolytes after transition.

3. Switch to Valsartan/HCTZ (Diovan HCT)

Valsartan/HCTZ provides equivalent ARB + diuretic coverage in patients with ACE inhibitor intolerance. Available in 80/12.5mg, 160/12.5mg, 160/25mg, and 320/25mg strengths. Valsartan shares lisinopril's FDA indications for hypertension, heart failure, and post-MI left ventricular dysfunction. Do not combine with lisinopril (dual RAAS blockade).

4. Benazepril/HCTZ (Lotensin HCT)

For patients specifically requiring an ACE inhibitor/diuretic combination, Benazepril/HCTZ is a direct class equivalent. Note: benazepril is hepatically metabolized (unlike lisinopril, which is not). For patients with hepatic impairment, lisinopril components separately may be preferable. Strengths: 5/6.25mg, 10/12.5mg, and 20/25mg.

Key Prescribing Reminders

• Pregnancy: Discontinue immediately upon pregnancy detection. Both ACE inhibitors and ARBs cause fetal injury and death (Black Box Warning). Ensure contraception counseling for all patients of reproductive age.
• Renal function: Not recommended if CrCl < 30 mL/min. Loop diuretics preferred over thiazides in severe renal impairment.
• Angioedema: History of ACE inhibitor-related angioedema is an absolute contraindication. Higher incidence in Black patients. If angioedema occurred, switch to an ARB or a different drug class — never re-challenge with any ACE inhibitor.
• Dual RAAS blockade: Avoid concurrent ACE inhibitor + ARB or ACE inhibitor + aliskiren (especially in diabetics). Increases risk of hypotension, hyperkalemia, and renal impairment.
• Entresto interaction: Do not use sacubitril/valsartan (Entresto) within 36 hours of lisinopril — risk of angioedema.

How to Help Patients Find Their Medication

Direct patients to medfinder for providers at medfinder.com/providers. medfinder calls pharmacies near your patients to identify which ones have their medication in stock, texting results directly to the patient. This is particularly useful for patients who are mobility-limited, in rural areas, or who have already struck out at several local pharmacies.

For the patient-facing version of this information, see: Hydrochlorothiazide/Lisinopril Shortage Update: What Patients Need to Know in 2026